Tolerance to the repolarization effects of rac-sotalol during long-term treatment

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 463-470

  Padrini, Roberto ^a   Gusella, Milena ^b   Al Bunni, Muhammed ^b   Piovan, Donatella ^b   Zordan, Rossella ^b   Magnolfi, Gianna ^b   Maiolino, Pietro ^b   Ferrari, Mariano ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

QT interval; rac sotalol; Tolerance

Indexed keywords

SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HEART RATE; HUMAN; MAINTENANCE THERAPY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; REPOLARIZATION;

EID: 0030684774     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00604.x     Document Type: Article

References (31)

1. Fitton A, Sorkin EM. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 1993; 46: 678-719.
2. Mason JW, for the ESVEM investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 452-458.
3. Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J. Sotalol prolongation of the QTc interval in hypertensive patients. Clin Pharmacol Ther 1982; 32: 25-32.
4. Creamer JE, Nathan AW, Shennan A, Camm AJ. Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. AmJ Cardiol 1986; 57: 1092-1096.
5. Wang T, Bergstrand RH, Thompson KA, et al. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1988; 57: 1160-1165.
6. Mitchell LB, Wyse DG, Duff H. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 76: 810-818.
7. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991; 83: 536-545.
8. Le Coz F, Funck-Brentano C, Poirier JM, Kibleur Y, Mazoit X, Jaillon P. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy voluteers. Clin Pharmacol Ther 1992; 52: 417-426.
9. Masahiko K, Kazuo U, Yasuhido I, et al. Pharmacokinetics and pharmacodynamics of (±)-sotalol in healthy male vounteers. Br J Clin Pharmacol 1996; 42: 583-588.
10. Bowman WC, Rand MJ. Quantitative evaluation and statistical analysis of drug action. In Textbook of pharmacology, 2nd ed, eds Bowman WC, Rand MJ. Oxford, London, Edinburgh, Melbourne: Blackwell Scientific Publications, 1982: Chapter 41. pp. 41-44.
11. Carmeliet E. Electrophysiological and voltage clamp analysis of the effect of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 1985; 232: 817-825.
12. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 195-215.
13. Raine AE, Vaughan-Williams EM. Adaptational responses to prolonged beta-adrenoceptor blockade in adult rabbits. Br J Pharmacol 1980; 70: 205-218.
14. Way BP, Forfar JC, Cobbe SM. Comparison of the effects of chronic oral therapy with atenolol and sotalol on ventricular monophasic action potential duration and effective refractory period. Am Heart J 1988; 116: 740-746.
15. Edvardsson N, Olsson SB. Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br Heart J 1981; 45: 628-636.
16. Ward DE. Prolongation of the QT interval as an indicator of risk of a cardiac event. Eur Heart J 1988; 9(suppl. G), 139-144.
17. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985; 109: 568-574.
18. Staniforth DH, The QT interval and cycle length: the influence of atropine, hyoscine and exercise. Br J Clin Pharmacol 1983; 16: 615-621.
19. Lecocq B, Lecocq V, Jaillon P. Physiologic relation between cardiac cycle and QT duration in healthy volunteers. Am J Cardiol 1989; 64: 481-486.
20. Sarma JS, Venkataramen K, Samant DR, Gadgil UG. Effect of propranolol on the QT intervals of normal individuals during exercise: a new method for studying interventions. Br Heart J 1988; 60: 434-439.
21. Puddu PE, Jouve R, Mariotti S, et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia's equation. J Electrocardiol 1988; 21: 219-229.
22. Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 1976; 20: 278-289.
23. Whiting B, Holford NHG, Sheiner LB. Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol 1980; 9: 67-75.
24. Holford NHG, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationship. Br J Clin Pharmacol 1981; 11: 187-195.
25. Kautzner J, Yi G, Camm AJ, Malik M. Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. PACE 1995; 17: 928-937.
26. Taouis M, Sheldon RS, Duff HJ. Upregulation of the rat cardiac sodium channel by in vivo treatment with a class I antiarrhythmic drug. J Clin Invest 1991; 88: 375-378.
27. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
28. Antz M, Cappato R, Kuck KH. Metoprolol versus atenolol in the treatment of sustained ventricular tachycardia. J Cardiovasc Pharmacol 1995; 26: 627-635.
29. Senges J, Lengfelder W, Jauering R, et al. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 1984; 69: 577-584.
30. Jordaens LJ, Palmer A, Clement DL. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. Eur Heart J 1989; 10: 218-226.
31. Kus T, Campa MA, Nadeau R, Dubuc M, Kaltenbrunner W, Shenasa M. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artey disease. Am Heart J 1992; 123: 82-89.